Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) Return on assets
Merck & Co., Inc.'s return on assets over the twelve months to 30 June 2026 was 2.57%, down 11.8 percentage points from fiscal 2025 (14.4%). Over the past ten years it has ranged from 0.34% (fiscal 2023) to 15.3% (fiscal 2024); the current reading is higher than 91% of that period. That is in line with the Drug Manufacturers General industry median of 2.57% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.4% | (0.93) |
| FY2024 | 15.3% | 14.96 |
| FY2023 | 0.34% | (13.18) |
| FY2022 | 13.5% | 0.29 |
| FY2021 | 13.2% | 5.20 |
| FY2020 | 8.03% | (3.76) |
| FY2019 | 11.8% | 4.49 |
| FY2018 | 7.30% | 4.69 |
| FY2017 | 2.61% | (1.37) |
| FY2016 | 3.98% | (0.47) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| ABBV AbbVie Inc. compare | 4.61% |
| MRK Merck & Co., Inc. | 2.57% |
| PFE Pfizer Inc. compare | 2.13% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.57% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement